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ORIGINAL RESEARCH
Objective: Recently a number of new therapies have been introduced to treat psoriasis, but
concerns have been expressed about their high cost. The purpose of this study was to determine
whether most psoriasis treatments lie within the accepted range of cost-utility.
Methodology: 32 patients with moderate to severe psoriasis were administered the Euro-
Qol 5 Dimension (EQ-5D) survey to calculate their health state utility. Economic modeling
was performed with a range of therapeutic costs applying the calculated utility score. Paired
t-tests were used to calculate significance.
Results: At the conclusion of 2 weeks of therapy, the mean psoriasis area and severity index
(PASI) improved 35% to 7.2 (p<0.001). The mean health state utility score on the EQ-5D
improved 11.5% from 77.7 units before therapy to 86.7 units after therapy (p=0.007).
Conclusion: A therapy that achieves at least a PASI 35 would be considered cost-effective
by conventional standards if it does not exceed $33 600 in cost.
Keywords: psoriasis, cost-utility analysis, health economics
Introduction
Despite substantial efforts and policy changes during the past two decades, health
care costs continue to rise (Russell 1994). It is estimated that by 2011, healthcare
spending will exceed 15% of gross US domestic product (CMS 2004). The dramatic
rise in healthcare expenditure has been fueled by the development of novel
therapeutics. In psoriasis, for instance, recent years have seen the approval of 3
biologic response modifiers to treat the disease, all costing about US$10–20 000 per
year for medication alone, substantially increasing the direct cost of care from prior
estimates (Javitz et al 2002; Leonardi 2004; Rich 2004). Indeed, this can be compared
with the therapeutic cost of methotrexate, with all of its concomitant side effects, of
approximately US$1000/year (Opmeer et al 2004). Even prior to the development of
biologic therapy, the annual cost of treating psoriasis had been estimated at between
US$1.6 billion and US$3.2 billion (NPF 2006).
Utility is the preference of an individual for a particular health state or treatment
outcome. Utilities for a given health state have been measured using different
populations, including the general public, patients who have experienced the disease
state, and other surrogate respondents. Cost utility analysis (CUA) is a specific type
of cost-effectiveness analysis (CEA) using quality-adjusted life years as the
effectiveness endpoint. The cost-utility ratio is the incremental cost of an intervention
to achieve one quality adjusted life year, compared with an alternative intervention
(Guyatt et al 1993; Gold 1996).
The Euro-Qol 5 Dimension (EQ-5D) is a standardized generic instrument
developed for describing and valuing health states (EuroQol Group 1990). The EQ-
5D was developed for use in population health surveys or in conjunction with a
condition-targeted instrument for assessment of outcomes related to specific health
conditions or their treatment (Kind 1996). It specifically refers to health status at the
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time of questioning. The EQ-5D produces three types of
data for each respondent: (1) a description of the extent of
the problem along five health dimensions; (2) a population-
weighted health index; and (3) a self-rated assessment of
health status using a visual analog scale (VAS) (Kind 1996).
The utility measurement records a patient’s health state
along five dimensions (mobility, self-care, usual activities,
pain/discomfort, and anxiety/depression). Each dimension
has three levels reflecting no problem, some problem, and
extreme problem. Respondents are asked to indicate one of
the three levels along each of the five dimensions. This
classifies respondents into 1 of 125 distinct health states
(Dolan 1997). The applied valuation, to assign a utility to
each health state, was developed in the UK using the time
trade-off method (Dolan 1997). Utility measures, derived
from economic and decision theory, reflect the preferences
of patients for treatment process and outcome, thus
indicating the value of that health status to the patient.
Conventionally, an affordable healthcare intervention has
been defined as that which produces a single unit of health
state utility, the quality adjusted life year (QALY), for
between US$50 000 and US$100 000 (Ubel et al 2003). An
intervention that cures a patient of a health condition with a
quality of life halfway between perfect health and death
yields 0.5 QALYs per year. A return to perfect health yields
one QALY per year (Gold 1996).
The purpose of this study is to provide a preliminary
estimate of the cost-utility of therapy for psoriasis.
Methods
Thirty-two patients with moderate to severe psoriasis
were administered the EQ-5D survey to calculate their
health state utility during a randomized controlled trial
evaluating the efficacy of a topical therapy in different
formulations that was approved by the Stanford Panel
on Human Subjects. The methodology of this study has
been previously reported (Bergstrom et al 2003). In brief,
the study was a single-blind design in which 32 patients
were randomized into 2 groups and applied either
clobetasol foam 0.05% to the skin and scalp or
combination clobetasol cream 0.05% to the skin and
clobetasol solution 0.05% to the scalp. The treatment
period was 14 days and there were no significant
differences in the two randomized groups.
Established values for health utility were taken from the
published literature, including the value of no chronic
conditions (EuroQol Group 1990). The utility score was
calculated as the improvement in utility from the use of a
topical therapy that achieved a 35% improvement in
psoriasis area and severity index (PASI), divided by the
difference between the utility value of psoriasis with a mean
baseline PASI of 11 prior to treatment and the utility value
of having no chronic diseases. Economic modeling was
performed with a range of therapeutic costs applying the
calculated utility score. Paired t-tests were used to calculate
significance.
Results
The mean PASI at entry was 11.1 (Table 1). The mean health
state utility score on the EQ-5D for psoriasis was 77.7 units.
At the conclusion of 2 weeks of therapy, the mean PASI
was 7.2, a 35.0% improvement (p<0.001). The resulting
utility score on the EQ-5D, following therapy, was 86.7
units, an 11.5% improvement (p=0.007).
Table 1 Analysis
Abbreviations: BSA, body surface area; DLQI, Dermatology Life Quality Index; EQ5D, European QoL 5 Dimension survey; PASI, psoriasis area and severity index;
SAPASI, self-assessed psoriasis area and severity index; VAS, visual analog scale.
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During the 2 week study, total body surface improved
20.4% (p<0.001). Quality of life as measured by the
dermatology life quality index (DLQI) and the EQ-5D VAS
improved 40.2% and 8.2% respectively (p<0.001). The
patient’s perception of disease severity, as measured by the
self-assessed PASI (SAPASI), improved 26.2% (p=0.04).
The mean established value for individuals with no
chronic conditions is 91 units, 13.3 units more desirable
than having psoriasis with a PASI of 11.1. The 11.5%
improvement in psoriasis severity therefore corresponds to
a QALY score of 0.67. In other words, a therapy for psoriasis
that yields a 35% improvement in PASI results in an
incremental gain of 0.67 QALYs, two-thirds the value of
having no chronic conditions. Table 2 illustrates the
application of the calculated utility score to a range of
therapeutic costs, generating the cost-utility value of
proposed therapies. A therapy that achieves a 35%
improvement in PASI is considered cost-effective, defined
as a CUA less than US$50 000/QALY if it does not exceed
US$33 600 in cost. Moreover, therapy for psoriasis that
attains a PASI 35 has a more favorable cost-utility ratio than
other more commonly accepted healthcare interventions
including annual retinopathy screening for low risk patients
with diabetes (Table 3) (Ubel et al 2003).
Discussion
An affordable healthcare intervention is conventionally
defined in the US as that which yields a value of US$50 000/
QALY (Gold 1996; Ubel et al 2003). Based on this
preliminary cost-utility analysis, therapy for psoriasis that
achieves at least a PASI 35 and costs up to US$34 000
annually, is comparably affordable with treatments for other
medical conditions.
Importantly, a 35% reduction in PASI is a modest,
although meaningful, reduction of the extent of psoriasis.
Most new therapies have been judged on their ability to
produce a PASI 75. These results from this study are
therefore based on a degree of clearance that is clearly
clinically relevant, but is significantly less than the
improvement brought about by many systemic therapies.
Of note, for most people with a PASI of 11, topical therapy
is likely to be time-consuming and inconvenient – and might
have negatively impacted the level of improvement observed
during the two week treatment period compared with more
convenient therapies.
The QALY score for the current study is derived after 2
weeks of therapy, which is the US Food and Drug
Administration (FDA)-recommended duration of this
treatment. Typically in clinical practice, after improvement
is achieved, it is maintained with other topical medications.
With adequate compliance we would expect this QALY
score could be maintained over the course of a year of
treatment and might possibly improve, implying that cost-
effectiveness might increase over time.
This analysis is based upon the use of traditional
methodologies for analyzing the cost-utility of any given
treatment. There are several limitations to the application
of this analysis to psoriasis. First, the methodology does
not adjust for variations in the baseline utility scores at the
beginning of the treatment. Second, the methodology is most
rigorously applied to diseases in which a single treatment
leads to persistent health effects such as a cancer treatment
which brings remission. The translation into the analysis of
utility of treating chronic conditions, especially chronic
conditions which wax and wane, is complicated by difficulty
in determining how subjects will measure their utility over
time.
Table 3 Comparisons across disease – Health State Utility
(Ubel et al 2003)
Disease Utility Score
CABG for coronary artery disease 0.84
Medical subgroup refusing CABG for 0.74
Coronary Artery Disease
Psoriasis (PASI 35) 0.78
Medical management for Coronary Artery Disease 0.61
Abbreviations:  CABG, coronary artery bypass graft; PASI, psoriasis area and
severity index.
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24,000.00 $ 
30,000.00 $ 
34,000.00 $ 
8,925.08 $     
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26,775.24 $   
35,700.33 $   
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Table 2 Incremental cost-utility of a PASI 35 at different annual
costs of therapy
Abbreviations: CUA, cost-utility analysis; PASI, psoriasis area and severity
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Nonetheless, it is essential to continue to evaluate the
health-related quality of life experienced by patients with
psoriasis and other skin diseases, because despite the
assumption that these are problems of a strictly cosmetic
nature, they demonstrate significant impairment on health
state utility (Jenner et al 2002; Weiss et al 2002, 2003).
Moreover, the benefits achieved from therapy compare
favorably with therapies that are routinely covered by third
party payers. Therefore, the next step is to assess
prospectively the incremental benefit in health state utility
of psoriatic therapies by incorporating the EQ-5D into large
randomized controlled studies including phase III and IV
study protocols.
Today, more than ever before, dermatologists have been
provided the tools to improve significantly the physical
stigmata of psoriasis that affects its sufferers. These results
demonstrate that the value of medicines for treating psoriasis
provide utilities comparable with that of other therapies in
other areas of medicine.
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